Identification of a genomic region between SLC29A1 and HsP90AB1 associated with risk of bevacizumab-induced hypertension: CALGB 80405 (Alliance)

Megan Li, Flora Mulkey, Chen Jiang, Bert H. O'Neil, Bryan P. Schneider, Fei Shen, Paula N. Friedman, Yukihide Momozawa, Michiaki Kubo, Donna Niedzwiecki, Howard S. Hochster, Heinz Josef Lenz, James N. Atkins, Hope S. Rugo, Susan Halabi, William Kevin Kelly, Howard L. McLeod, Federico Innocenti, Mark J. Ratain, Alan P. VenookKouros Owzar, Deanna L. Kroetz

Research output: Contribution to journalArticle

Abstract

Purpose: Bevacizumab is a VEGF-specific angiogenesis inhibitor indicated as an adjunct to chemotherapy for the treatment of multiple cancers. Hypertension is commonly observed during bevacizumab treatment, and high-grade toxicity can limit therapy or lead to cardiovascular complications. The factors that contribute to interindividual variability in blood pressure rise during bevacizumab treatment are not well understood. Experimental Design: To identify genomic regions associated with bevacizumab-induced hypertension risk, sequencing of candidate genes and flanking regulatory regions was performed on 61 patients treated with bevacizumab (19 cases developed early-onset grade 3 hypertension and 42 controls had no reported hypertension in the first six cycles of treatment). SNP-based tests for common variant associations and gene-based tests for rare variant associations were performed in 174 candidate genes. Results: Four common variants in independent linkage disequilibrium blocks between SLC29A1 and HSP90AB1 were among the top associations. Validation in larger bevacizumab-treated cohorts supported association between rs9381299 with early grade 3þ hypertension (P ¼ 0.01; OR, 2.4) and systolic blood pressure >180 mm Hg (P ¼ 0.02; OR, 2.1). rs834576 was associated with early grade 3þ hypertension in CALGB 40502 (P ¼ 0.03; OR, 2.9). These SNP regions are enriched for regulatory elements that may potentially increase gene expression. In vitro overexpression of SLC29A1 in human endothelial cells disrupted adenosine signaling and reduced nitric oxide levels that were further lowered upon bevacizumab exposure. Conclusions: The genomic region between SLC29A1 and HSP90AB1 and its role in regulating adenosine signaling are key targets for further investigation into the pathogenesis of bevacizumab-induced hypertension.

Original languageEnglish (US)
Pages (from-to)4734-4744
Number of pages11
JournalClinical Cancer Research
Volume24
Issue number19
DOIs
StatePublished - Oct 1 2018

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Identification of a genomic region between SLC29A1 and HsP90AB1 associated with risk of bevacizumab-induced hypertension: CALGB 80405 (Alliance)'. Together they form a unique fingerprint.

  • Cite this

    Li, M., Mulkey, F., Jiang, C., O'Neil, B. H., Schneider, B. P., Shen, F., Friedman, P. N., Momozawa, Y., Kubo, M., Niedzwiecki, D., Hochster, H. S., Lenz, H. J., Atkins, J. N., Rugo, H. S., Halabi, S., Kelly, W. K., McLeod, H. L., Innocenti, F., Ratain, M. J., ... Kroetz, D. L. (2018). Identification of a genomic region between SLC29A1 and HsP90AB1 associated with risk of bevacizumab-induced hypertension: CALGB 80405 (Alliance). Clinical Cancer Research, 24(19), 4734-4744. https://doi.org/10.1158/1078-0432.CCR-17-1523